Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.40 |
| ▸ | NOS3 | P29474 | 4/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24756842 | 0.83 | HSP90AA1 (0.38) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL18310656 | 0.81 | NOS2 (0.41) | NOS2NOS3NOS1BACE1PRMT5 | |
| SCHEMBL31234990 | 0.80 | HSP90AA1 (0.36) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL24615642 | 0.80 | HSP90AA1 (0.36) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL29851065 | 0.80 | HSP90AA1 (0.36) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL22028956 | 0.80 | HSP90AA1 (0.36) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL22028950 | 0.80 | HSP90AA1 (0.36) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL29936752 | 0.80 | HSP90AA1 (0.36) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL21733359 | 0.79 | HSP90AA1 (0.35) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL26707264 | 0.79 | BACE1 (0.42) | NOS2NOS3NOS1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024138486-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024054926-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024040080-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023284730-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022081655-A1 | SUBSTITUTED DIHYDROPYRANOPYRIMIDINE COMPOUNDS AS KRAS INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| WO-2021219090-A1 | QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN | 北京泰德制药股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NOS2 4773/4885NOS3 4724/4885NOS1 4705/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NOS2 4639/4885NOS3 4599/4885NOS1 4548/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | NOS2 3912/4885NOS3 3905/4885NOS1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.